Literature DB >> 24798316

Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity.

Rhett M Cook1, Matthew T Rondina1, Devin J Horton2.   

Abstract

OBJECTIVE: To report a case where rivaroxaban was used in the management of an ovarian vein thrombosis and to briefly review the literature, pathophysiology, and clinical implications therein. CASE
SUMMARY: A 30-year-old previously healthy woman was diagnosed with acute, spontaneous, left-ovarian vein thrombosis (OVT) with proximal extension into the renal vein. After initial catheter-directed thrombolysis with tPA, angioplasty of the left renal vein, and heparinoid treatment, rivaroxaban was begun for long-term anticoagulation. Three months after her index event she was symptom free, with complete resolution of her thrombosis and no adverse effects or bleeding complications from rivaroxaban. To our knowledge, this is the first report of OVT successfully treated with rivaroxaban. DISCUSSION: OVT is a rare but potentially fatal cause of abdominal pain that may pose diagnostic and therapeutic dilemmas. Factor V Leiden (FVL) homozygosity, an uncommon but severe inherited thrombophilia, increases the risk of thrombosis by approximately 50- to 80-fold. This case report and accompanying literature review highlight important clinical pearls related to the diagnosis and management of OVT and inherited thrombophilias.
CONCLUSIONS: This clinical vignette adds to the published literature suggesting that novel oral anticoagulants, such as rivaroxaban, may eventually emerge as an alternative to vitamin K antagonists for the treatment of extra-axial thromboses. Reporting these cases is important because their prevalence is low outside of specialized referral centers, and thus, dissemination of these experiences may help other providers in treating their patients.
© The Author(s) 2014.

Entities:  

Keywords:  anticoagulation; factor V Leiden; ovarian vein thrombosis; rivaroxaban; thrombophilia

Year:  2014        PMID: 24798316     DOI: 10.1177/1060028014533304

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

Review 1.  The use of direct oral anticoagulants in inherited thrombophilia.

Authors:  Jessica W Skelley; C Whitney White; Angela R Thomason
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

2.  Ovarian Vein Thrombosis as a Complication of Laparoscopic Surgery.

Authors:  Anu Gupta; Natasha Gupta; Josef Blankstein; Richard Trester
Journal:  Case Rep Obstet Gynecol       Date:  2015-12-14

Review 3.  Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.

Authors:  Peter P Toth
Journal:  Vasc Health Risk Manag       Date:  2016-02-10

4.  A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~.

Authors:  Daisuke Sueta; Miwa Ito; Mitsuhiro Uchiba; Kenji Sakamoto; Eiichiro Yamamoto; Yasuhiro Izumiya; Sunao Kojima; Koichi Kaikita; Satoru Shinriki; Seiji Hokimoto; Hirotaka Matsui; Kenichi Tsujita
Journal:  Thromb J       Date:  2017-03-14

5.  Novel management of ovarian vein thrombosis: A case report.

Authors:  Joseph Naoum; Amani Mohsen; Jihad Daher; Toufic Eid
Journal:  Saudi Pharm J       Date:  2018-03-07       Impact factor: 4.330

6.  Direct oral anticoagulants for unusual-site venous thromboembolism.

Authors:  Nicoletta Riva; Walter Ageno
Journal:  Res Pract Thromb Haemost       Date:  2021-01-28

Review 7.  Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

Authors:  Lina Khider; Nicolas Gendron; Laetitia Mauge
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 8.  Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.

Authors:  Konstantinos N Aronis; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2018-01-26       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.